Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

3cl protease Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV Protease (12) HIV Protease (12) Virus Protease (4) Apoptosis (5) Cathepsin (2) Cytochrome P450 (2) Endogenous Metabolite (2) HCV (12) HIV (12) HSV (2) Isotope-Labeled Compounds (1) MMP (3) P-glycoprotein (2) SARS-CoV (49)
By Research Areas:	Cancer (12) Infection (47) Inflammation/Immunology (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Virus Protease HCV Protease HIV Protease Protease Activated Receptor (PAR) Ser/Thr Protease ClpP Enteropeptidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17007

Saquinavir 5+ Cited Publications Ro 31-8959	HIV HIV Protease SARS-CoV	Infection Cancer
Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 1.36 μM.

HY-157778

MK-7845

SARS-CoV Infection

MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ of 8.7 nM .

MK-7845	SARS-CoV	Infection
MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ of 8.7 nM .

HY-150691

SARS 3CLpro-IN-1	SARS-CoV	Cancer
SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC₅₀ value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .

HY-147020

Coronastat NK01-63	SARS-CoV	Infection
Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .

HY-144062

INSCoV-614(1B)	SARS-CoV	Infection
INSCoV-614(1B) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-90001

Ritonavir 20+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 1.61 μM.

HY-156654

Ibuzatrelvir PF-07817883	SARS-CoV Virus Protease	Infection
Ibuzatrelvir (PF-07817883) is an antiviral agent, targeting to SARS-CoV-2 3CL protease. Ibuzatrelvir can be used to inhibit COVID-19 .

HY-144061

INSCoV-601I(1)	SARS-CoV	Infection
INSCoV-601I(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144063

INSCoV-600K(1)	SARS-CoV	Infection
INSCoV-600K(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of *SARS-CoV-2 3CL* ^pro*. 3CL* ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-143216

Ensitrelvir 5+ Cited Publications S-217622	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-143216A

Ensitrelvir fumarate 5+ Cited Publications S-217622 fumarate	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-152009

SARS-CoV-2 3CLpro-IN-7

SARS-CoV Infection

SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 1.4 µM .

SARS-CoV-2 3CLpro-IN-7	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 1.4 µM .

HY-137048

PF-00835231 1 Publications Verification	SARS-CoV	Infection
PF-00835231 is a CoV-2 *cysteine 3C-like protease* (3CL ^pro)** inhibitor, with IC₅₀s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL ^pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19 sup>[2].

HY-17430

Amprenavir 5+ Cited Publications VX-478	HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 1.09 μM.

HY-153228

Pomotrelvir PBI-0451	SARS-CoV	Infection
Pomotrelvir (PBI-0451) is a selective, orally active SARS-CoV-2 3CL protease inhibitor. Pomotrelvir has antiviral activity and can be used in the research of novel coronavirus (COVID-19) .

HY-17634

Glecaprevir 5 Publications Verification ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 4.09 μM .

HY-152005

SARS-CoV-2 3CLpro-IN-6	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL ^pro with an IC₅₀ value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-10300

Narlaprevir 4 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 2.3 μM .

HY-90001R

Ritonavir (Standard) ABT 538 (Standard); RTV (Standard)	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (Standard) is the analytical standard of Ritonavir. This product is intended for research and analytical applications. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 1.61 μM.

HY-14434

Asunaprevir 30+ Cited Publications BMS-650032	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC₅₀ of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-146998

SARS-CoV-2 3CLpro-IN-2	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .

HY-156651

Zevotrelvir	SARS-CoV	Infection
Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC₅₀ ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections .

HY-15148

Tipranavir 5+ Cited Publications PNU-140690	HIV Protease HIV SARS-CoV	Infection
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC₅₀s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL ^pro activity .

HY-149264

SARS-CoV-2 3CLpro-IN-13	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .

HY-138687

Nirmatrelvir Maximum Cited Publications 44 Publications Verification PF-07321332	SARS-CoV	Infection Inflammation/Immunology
Nirmatrelvir (PF-07321332) is a potent and orally active *SARS-CoV 3C-like protease* (3CL ^PRO)** inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .

HY-151535

SARS-CoV-2 3CLpro-IN-5	SARS-CoV	Infection Inflammation/Immunology
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of *3C-like protease* (3CL ^pro)*. SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL* ^pro with an IC₅₀ value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 3.49 μM .

HY-10237

Boceprevir 25+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-149767

CMX990	SARS-CoV	Infection
CMX990 is a SARS-CoV-2 3CL protease inhibitor. The EC90s for inhibiting SARS-CoV-2 were 9.6 nM and 101 nM in human bronchial epithelial cells (HBECs) and HeLa-ACE2 cells, respectively. CMX990 has good ADME and pharmacokinetic properties .

HY-B0689

Indinavir MK-639 free base; L-735524 free base	HIV HIV Protease Apoptosis MMP SARS-CoV	Inflammation/Immunology Cancer
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a *SARS-CoV 3CL* ^pro** inhibitor .

HY-10235

Telaprevir 40+ Cited Publications VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-14588

Lopinavir 10+ Cited Publications ABT-378	HIV HIV Protease SARS-CoV	Infection Cancer
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 14.2 μM .

HY-B0689A

Indinavir sulfate 5+ Cited Publications MK-639; L735524	HIV HIV Protease SARS-CoV Apoptosis MMP	Infection Cancer
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a *SARS-CoV 3CL* ^pro** inhibitor .

HY-B0689B

Indinavir sulfate ethanolate MK-639 ethanolate; L735524 ethanolate	Apoptosis MMP HIV HIV Protease SARS-CoV	Infection Cancer
Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a *SARS-CoV 3CL* ^pro** inhibitor .

HY-14588R

Lopinavir (Standard) ABT-378 (Standard)	HIV HIV Protease SARS-CoV	Infection Cancer
Lopinavir (Standard) is the analytical standard of Lopinavir. This product is intended for research and analytical applications. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 14.2 μM .

HY-W760546

SARS-CoV-2 3CLpro-IN-15	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-15298

Grazoprevir 20+ Cited Publications MK-5172	HCV Protease HCV SARS-CoV	Infection
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-15298A

Grazoprevir potassium salt 20+ Cited Publications MK-5172 potassium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir potassium salt inhibits SARS-CoV-2 3CL ^pro activity .

HY-15298C

Grazoprevir sodium salt MK-5172 sodium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir sodium salt inhibits SARS-CoV-2 3CL ^pro activity .

HY-15298B

Grazoprevir hydrate 20+ Cited Publications MK-5172 hydrate	HCV HCV Protease SARS-CoV	Infection
Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir hydrate inhibits SARS-CoV-2 3CL ^pro activity .

HY-14588S

(rel)-Lopinavir-d8 (rel)-ABT-378-d₈	Isotope-Labeled Compounds	Others
(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 14.2 μM .

HY-108137

Z-LVG-CHN2 2 Publications Verification	Cathepsin HSV SARS-CoV	Infection Inflammation/Immunology
Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease .

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-12594A

Paritaprevir dihydrate ABT-450 dihydrate; Veruprevir dihydrate	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-10238

Danoprevir 15+ Cited Publications ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 0.05 μM .

HY-108137A

Z-L(D-Val)G-CHN2	Cathepsin HSV SARS-CoV	Infection
Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a *SARS-CoV 3CL* ^pro** inhibitor with an IC₅₀ of 3.49 μM .

Cat. No.	Product Name	Chemical Structure

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks